Akeso Inc. Announces Positive Results from Global Phase III HARMONi Trial of Ivonescimab, Demonstrating Improved Overall Survival in Lung Cancer Patients
I'm PortAI, I can summarize articles.
Akeso, Inc. announced positive results from the global Phase III HARMONi trial of ivonescimab, showing improved overall survival in lung cancer patients. The trial revealed a hazard ratio of 0.78 and a median overall survival of 17.0 months for patients receiving ivonescimab, compared to 14.0 months for those on placebo. The findings indicate consistent benefits across subgroups. Additionally, the HARMONi-A study in China has reached its overall survival clinical endpoint, with results to be shared at future conferences.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments